Osang HealthCare Co Ltd

Osang HealthCare maintains a conservative capital structure with a debt-to-equity ratio of 0.16, indicating limited leverage. The company's liquidity position is characterized as medium risk, with a current ratio of 4.22, suggesting strong short-term asset coverage over liabilities. However, the company reported negative free cash flow of -15,321,908,900 KRW, driven by capital expenditures of -19,009,719,320 KRW, which may pressure near-term liquidity. Profitability metrics show a return on equity (ROE) of 1.11% and return on assets (ROA) of 0.92%, both below the typical thresholds for high-margin healthcare equipment firms. The company's gross margin is 44.4% (57,144,758,600 KRW gross profit on 128,628,728,660 KRW revenue), but operating margin is only 8.05% (10,356,770,740 KRW operating income), indicating operational inefficiencies or competitive pricing pressures. The company operates through three segments: Biochemical Diagnostic, Immunodiagnostic, and Molecular Diagnostic. Revenue concentration data is not disclosed, but the firm's exposure to the Korean market is likely high, as it is a domestic-based firm with no material international revenue disclosed in the financial snapshot. This geographic concentration may expose the company to local regulatory and economic risks. Outlook data is not provided in the input, but the company's free cash flow and capital expenditure trends suggest a capital-intensive growth strategy. The price-to-earnings ratio of 37.95 and price-to-book ratio of 0.42 indicate a relatively high valuation multiple compared to book value, but a moderate multiple relative to earnings. The risk assessment highlights a key flag: net cash is negative after subtracting total debt, which may signal potential liquidity constraints if cash flow does not improve. The dilution risk is assessed as low, with no near-term dilution pressure indicated in the data. Recent events are not detailed in the input, but the company's capital expenditures and negative free cash flow suggest ongoing investment in R&D and production capabilities, which may be disclosed in upcoming filings or investor communications.